Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
0.978
-0.082 (-7.73%)
At close: Dec 20, 2024, 4:00 PM
0.990
+0.012 (1.21%)
After-hours: Dec 20, 2024, 5:15 PM EST
Citius Oncology Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Citius Oncology stock have an average target of 4.50, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 360.08% from the current stock price of 0.98.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTOR stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 |
---|---|---|---|
Strong Buy | 1 | 2 | 2 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 1 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +206.72% | Nov 27, 2024 |
EF Hutton | EF Hutton | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +513.43% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.